REFERENCES

DROPS: 1. Indrio F et al. Eur J Clin Invest. 2011;41:417–422. 17. Indrio F et al. J Pediatr. 2008;152:801–806. (in Biogaia FGIDs in infants Jan 2021); 2. Savino F, et al. Crying time and RORy/FOXP3 expression in Lactobacillus reuteri DSM 17938-treated infants with colic: A randomized trial. J Pediatr 2018;192:171-177.

FEMME: 1. Gardiner GE, Heinemann C, Bruce AW, et al. Persistence of Lactobacillus fermentum RC-14 and Lactobacillus rhamnosus GR-1 but not L. rhamnosus GG in the human vagina as demonstrated by randomly amplified polymorphic DNA. Clin Diagn Lab Immunol 2002:92-96; 2. Reuterina Femme® Approved Package Insert, December 2009;

3. Gardiner GE, Heinemann C, Baroja ML, et al. Oral administration of the probiotic combination Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 for human intestinal applications. Int Dairy J 2002;12:191-196. 4. Anukam KC, Duru MU, Eze CC, et al. Oral use of probiotics as an adjunctive therapy to fluconazole in the treatment of yeast vaginitis: A study of Nigerian Women in an outdoor clinic. Microbial Ecology in Health and Disease 2009;21:72-77.

JUNIOR: 1. Romano C, Ferrau V, Cavataio F, et al. Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatric Child Health 2014;50(10):E68-E71;

2. Reuterina Junior® Approved Package Insert, July 2010; 3. Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria, October 2001. http://www.who.int/foodsafety publications fs_management/en/ probiotics.pdf.